Pharmacokinetics of Reboxetine in Volunteers with Hepatic Impairment
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Objective: Reboxetine is a unique selective norepinephrine (noradrenaline) reuptake inhibitor (selective NRI) that is effective and well tolerated at a dosage of 8 to 10 mg/day in the short- and long-term treatment of depression. The objective of the study was to assess reboxetine pharmacokinetics in patients with moderate to severe hepatic impairment.
Design: 12 volunteers with alcoholic liver disease received a single 4mg dose of reboxetine, and plasma reboxetine concentrations were measured by high performance liquid chromatography.
Results: Reboxetine was well tolerated by all recipients. Compared with the pharmacokinetics of reboxetine 4mg determined in a similar study in young healthy volunteers, maximum concentration (Cmax) was up to 22% lower in patients with liver disease, the area under the plasma reboxetine concentration-time curve extrapolated to infinity (AUC∞) was up to 92% higher, and the terminal elimination half-life (t1/2z) was up to 150% longer. When comparing volunteers with moderate (Child-Pugh score 7 to 8) and severe hepatic (Child-Pugh score 10 to 13) impairment, mean Cmax was 21% lower, mean AUC∞ was 10% greater and t1/2,z was 23% longer in the severely impaired compared with the moderately impaired patients. Although none of these differences was statistically significant, the trend is of clinical relevance.
Conclusions: The severity of alcoholic liver disease does not appear to affect reboxetine pharmacokinetics in a statistically significant manner, but there is a clinically relevant trend in changes to reboxetine pharmacokinetics with increasing hepatic impairment. Although reboxetine 4mg was well tolerated in the present study, comparisons with historical data from young healthy volunteers suggest that a lower starting dosage of reboxetine (4 mg/day in divided doses) should be used in patients with hepatic impairment.
- Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997; 11(4 Suppl.): S9–S15
- Mucci M. Reboxetine: a review of antidepressanttolerability. J Psychopharmacol 1997; 11(4 Suppl.): S33–S37
- Edwards DMF, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxetine in healthy volunteers: single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 1995; 16: 443–60 CrossRef
- Pellizzoni C, Strolin Benedetti M, Poggesi I, et al. Pharmacokinetics of reboxetine in healthy volunteers: relative bioavailability and food effect. Pharmacol Res 1995; 31 Suppl.: 41 CrossRef
- Dostert P, Benedetti MS, Poggesi I. Review of pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7: S23–S35 CrossRef
- Sherlock S. Drugs and the liver. In: Diseases of the liver and biliary system, 8th edition. Oxford: Blackwell Scientific Publications, 1989: 372–409
- Child CJ. The liver and portal hypertension. Philadelphia: Saunders, 1964
- Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646–9 CrossRef
- Jannuzzo MG, Ryde M, Karlmark B, et al. Pharmacokinetics of reboxetine in healthy volunteers of different ages [abstract P-2-77]. Eur Neuropsychopharmacol 1995; 5(3): 300
- Tsujimoto G, Hashimoto K, Hoffman BB. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age. Pt 1. Int J Clin Pharmacol Ther Toxicol 1989; 27: 13–26
- Pellizzoni C, Poggesi I, Jørgensen NP, et al. Pharmacokinetics of reboxetine in healthy volunteers: single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Dispos 1996; 17: 623–33 CrossRef
- Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481–508 CrossRef
- Demolis JL, Angebaud P, Grangé JD, et al. Comparison of pharmacokinetics of orally administered sertraline in patients with stable chronic hepatic insufficiency and in healthy subjects. Fundam Clin Pharmacol 1993; 7: 355
- Pharmacokinetics of Reboxetine in Volunteers with Hepatic Impairment
Clinical Drug Investigation
Volume 19, Issue 6 , pp 473-477
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Author Affiliations
- 1. Centre d’Investigation Clinique, Service d’Hépato-Gastro-Entérologie et de Nutrition, Hôpital de l’Archet, Route de St Antoine Ginestière, BP 689, 06012, Nice Cedex, France
- 2. ADME Bioanalyses SA, Mougins, France
- 3. Clinical Research, Pharmacia & Upjohn SpA, Milan, Italy
- 4. Clinical Pharmacokinetics, Pharmacia & Upjohn Inc, Kalamazoo, Michigan, USA
- 5. Laboratoire de Pharmacocinétique et de Toxicologie Clinique, Centre Hospitalier Universitaire de Toulouse, Toulouse, France